8-K

UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Sight Sciences, Inc.

(Exact name of Registrant as Specified in Its Charter)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Compensatory Arrangements of Certain Executive Officers

On January 24, 2025, the Compensation Committee (the “Compensation Committee”) of the Board of Directors of Sight Sciences, Inc. (the “Company”) approved annual base salaries and target cash incentive bonus opportunities for the fiscal year ending December 31, 2025 (“Fiscal 2025”) for certain of the Company’s executive officers, including Paul Badawi, the Company’s President and Chief Executive Officer, Alison Bauerlein, the Company’s Chief Financial Officer and Treasurer, and Matthew Link, the Company’s Chief Commercial Officer.

Fiscal 2025 Base Salary

The annual base salary amounts received for the fiscal year ended December 31, 2024 (“Fiscal 2024”) and to be received for Fiscal 2025 by Mr. Badawi, Ms. Bauerlein, and Mr. Link are set forth opposite their names in the table below:

Fiscal 2025 Cash Incentive Program

The Company maintains an annual cash incentive program for all employees who are not eligible for commissions and who are otherwise eligible to participate in the program, including Mr. Badawi, Ms. Bauerlein, and Mr. Link.

The target bonus opportunity is set as a percentage of the participant’s base salary for the year as determined by the Compensation Committee. The Compensation Committee approved the following Fiscal 2025 target bonus opportunities for Mr. Badawi, Ms. Bauerlein, and Mr. Link, as set forth opposite their respective names in the table below:

The Fiscal 2025 cash incentive program applicable to executive officers will be earned based exclusively on achievement by the Company of specified predetermined milestones relating to revenue, adjusted operating expense, key market access milestones, key clinical and R&D milestones, and key commercial launch milestones.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.